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ABSTRACT 
Urolithiasis is the formation of renal calculi within the urinary tract of susceptible individual of various etiopathogenic factors with a complex 
pathogenic manifestation. It is a worldwide problem which was evident from the ancient times of Egyptian period. It is the third most urinary 
disorder with a lifetime risk of 15-25% and the prevalence rate of 3-5%. In the management of urolithiasis, the clinicians face a deprived status of 
mind with its multifactorial etiopathogenesis. Thus the exact therapy still remains to be debated with this modest understanding of pathophysiology 
and genetical aspects of urolithiasis. As a result of these poor understandings, an attempt was made to detail the multifactorial etiopathogenesis and 
genetical aspects of urolithiasis with a view to advancement in the clinical management. Moreover to this attempt, this review also summarized the 
updated clinical management in terms of specific and surgical measures along with its differential diagnosis to the extent of intending an immense 
sound over its management to the clinicians. 
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INTRODUCTION 
Urolithiasis also known as uroliths or calculi, the third most common 
prevalent urinary disorder that involves the process of stone 
formation in any part of urinary tract by the successive 
physiochemical events of supersaturation, nucleation, aggregation, 
and retention at the site of stone formation [1, 2]. It is a multifactorial 
disorder that results from multifactorial etiopathogenesis like 
epidemiological, biochemical, metabolic, nutritional, socio-economic, 
drug induced and genetical risk factors [3, 4].  
The supersaturation of urine with stone forming elements like 
calcium oxalate, struvite, uric acid, and cystine tends to be a key 
pathological event in stone formation [5]. It affects about 13% in 
North America, 5-9% in Europe, 1-5% in Asia [6]. Globally it affects 
about 10-12% of the population especially in the industrialized 
countries. Besides that, in the last five decades the incidence has 
been increased along with economic development in the Western 
countries [7]. The recurrence rate was reported to be 40% within 3 
years, 74% within 10 years and 98% within 25 years of the first 
incidence of urolithiasis [8]. Predominantly the incidence factor in 
the implication of urolithiasis is dependent greatly on age and 
gender factors [9]. But clinically the incidence was remained to be 
rare in children [10]. Urolithiasis often leads to other pathological 
implications like pyelonephritis, acute or chronic renal failure, 
pyonephrosis and perinephric abscess which can be life threatening 
complications [11]. 
Epidemiology 
The intrinsic factors need to consider the epidemiology of 
urolithiasis are age. Sex and genetic perspectives of an individual. 
The incidence rate is very high at the age of 20-40 years; and in men 
rather than women due to increased testosterone induced hepatic 
oxalate production in men. While the extrinsic factors in 
epidemiology are geography, climate, season, diet, water intake, 
occupation and stress. Geographically the incidence is more in USA, 
Mediterranean countries, and Central Europe, whereas the lower 
incidence was reported at Central and South America and Africa. Hot 
climatic conditions tend to concentrate the urine which acidifies and 
saturates the crystal forming elements to precipitate. Increased 
intake of animal protein, salt and sugar causes increased excretion of 
urinary calcium, uric acid, and oxalate that predisposes to incidence 
of renal calculi. The other extrinsic factors like low fluid intake, 
sedentary occupation and stress can predispose to uroliths [12]. 
Types of stones 
A. Physiologically 
Physiologically the renal calculi differentiated as tissue attached and 
unattached.  
1. Attached calculi tend to have the detectable site of attachment to 
papillae with the composition of calcium oxalate (CaOx) 
monohydrate.  
2. While the unattached calculi distinguished by having different 
composition and lack of detectable site [13].  
B. Clinically 
Based on the composition of the stone forming element in the 
calculi, clinically these calculi are categorized as following types. 
• Calcium stones (CaOx alone/with calcium phosphate) 
• Struvite stones (Magnesium ammonium phosphate) 
• Uric acid stones 
• Cystine stones 
• Drug induced stones 
• 2,8-Dihydroxyadenine stones 
Among the kidney stones, CaOx stones constitute about 75%, 
struvite stones of 15%, uric acid stones of about 6% and cystine 
stones of about 1-2% [14]. 
Calcium stones 
The Idiopathic causes are absorptive hypercalciuria, renal 
hypercalciuria and resorptive hypercalciuria. The metabolic causes 
are hypercalcaemia due to primary hyperparathyroidism, 
hyperoxaluria, hyperuricosuria, hypocitraturia and 
hypomagnesuria. In explaining the detail cause of each event- i. 
Hyperoxaluria arises due to primary hyperoxaluria of genetic 
disorder which enhances the hepatic oxalate production and enteric 
hyperoxaluria, where the colon is made to diffuse more oxalate. ii. 
Hyperuricosuria evident from excessive purine intake. iii. 
Hypocitraturia arises due metabolic acidosis induced by 
inflammatory bowel disease and chronic diarrhea. iv.  
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Hypomagnesuria be due to malabsorption of magnesium from gut 
because of inflammatory bowel disease and chronic diarrhea [15]. 
In hypercalciuria, calcium promotes the ionization and saturation of 
crystallization of calcium salts and also to bind with stone inhibiting 
substances such as citrates and glycosaminoglycans there by the 
events of hypercalciuria induced uroliths. The renal leak from 
kidney, resorption from bone and absorption from gut tends to be 
the key defects in implicating the hypercalciuria individually or in 
combination with each other [16]. In the other way, excessive 
dietary sodium intake predispose to uroliths by hypercalciuria and 
hypocitraturia. Moreover there exists a linear relationship between 
urinary sodium and calcium levels, which establish a strong 
relationship to confer risk of hypercalciuria induced uroliths [17, 
18]. In addition to the above all etiological factors, protein overload 
and metabolic acidosis are the other possible etiological factors in 
the pathogenesis of hypercalciuria induced calcium nephrolithiasis. 
In metabolic acidosis, the high urinary pH favors the formation of 
calcium containing uroliths [19]. The excess protein intake can 
predispose to calcium nephrolithiasis which was evident from 
animal, metabolic and epidemiological studies [20-23]. 
Hypocitraturia corresponds about 20-60% of calcium 
nephrolithiasis. As it is a major inhibitory component of calcium 
oxalate and calcium phosphate, lowered levels of citrate favors the 
risk of hypercalciuria induced calcium uroliths. Furthermore, the 
citrate tends to complex with calcium to form a soluble complex to 
prevent the crystal growth [24]. Hyperoxaluria, the another 
etiological factor of equal importance with hypercalciuria in 
inducing calcium nephrolithiasis by promoting the CaOx 
supersaturation in urine [25]. It occurs as a result of dietary intake 
of oxalate rich foods of spinach, rhubarb, beetroot, Almond, nuts, etc. 
Hyperuricosuria, as a result of high dietary intake of protein can 
attribute CaOx uroliths by the heterogeneous nucleation of uric acid 
[26]. 
Struvite stones 
These are also called as infectious stones, as a consequence of 
persistent urease producing bacterial infections. Generally these 
urease infections are caused by certain species of bacteria like E. coli, 
P. mirabilus, Pseudomonas species, Staphylococcal species and 
Ureaplasma urealyticum [27]. By secreting urease enzyme, these 
bacterial species hydrolyses the urea to carbon dioxide and 
ammonia which can raise the urinary pH to favor the struvite stones 
formation [28]. Infectious stones induced by these bacterial 
infections are caused by the urinary tract obstructions due to 
ureteropelvic junction stenosis, urinary catheters, the neurogenic 
bladder dysfunctioning, vesical ureteral reflux, medullary sponge 
kidney and distal renal tubular acidosis [29, 30].  
Uric acid stones 
Uric acid stones are clinically evident when there was increased 
hyperuricosuria, acidic urine and reduced volume of urine. Indeed 
the hyperuricosuria along with the aciduria clinically manifests the 
uric acid stones significantly. While the elevated levels of uric acid 
within normal pH can be tolerated. But hyperuricosuria seem to be a 
sole cause for uric acid uroliths in rare conditions [31]. The common 
etiological factors in inducing the uric acid uroliths are dietary 
intake of excess protein food, gout and recurrent monoarthritis 
along with acidic urine [32]. In addition, high body-mass index, type 
2 diabetes and glucose intolerance are most commonly seen in 
patients of uric acid uroliths [33-35]. 
In particularly obesity and type 2 diabetes conditions, impaired 
renal ammonium excretion and increased net acid production 
resulting in aciduria can favor the uric acid uroliths formation when 
it is associated with hyperuricosuria. The other causative factors like 
chronic diarrhea, gastroenterostomy, exercise induced lactic 
acidosis and high consumption of animal protein can predispose to 
acidic urine. Reduced urinary volume occurs as a result of chronic 
diarrhea, excessive perspiration and intestinal ostomies can acts as 
contributing factors in attributing the uric acid uroliths. The 
congenital enzymatic deficiencies, uricosuric agents, gout, 
myeloproliferative disorders, hemolytic anaemia and chemotherapy 
induced tumor lysis acts as the risk factors of hyperuricosuria 
induced uric acid stones [36, 37]. 
Cystine stones  
It constitutes of about only least amount in all types of stones which 
occurs in individuals having cystinuria, an autosomal recessive 
disease which affects proximal tubular absorption of cystine. The 
solubility of cystine is about 243mg/L in normal urinary pH, while 
the solubility greatly increased by increasing the urinary pH. 
Moreover cystine being as a poorly soluble amino acid form, it tends 
to form cystine stones more at lower urinary acidic pH [38]. It is also 
occurred as an autosomal recessive disorder of ornithine, arginine 
and lysine [39]. It affects about 1 in 20,000 individuals especially at 
an age of 20-30 years [40]. They are presented as staghorn stones 
which are multiple and radio-opaque. 
Drug induced stones 
These constitute the rare forms of stones which are drug induced 
forms that results from various drugs like indanavir, triamterine, 
flouroquinolones, primidone, tetracyclines, magnesium trisilicate 
and sulfonamides. In addition to this, other drugs like calcitriol, 
corticosteroids, furosemide and acidifiers can predispose the 
individual to hypercalciuria induced calcium uroliths. In other cases 
like ascorbic acid and allopurinol therapy, there exist implications of 
hyperoxaluria and hyperxanthuria induced lithogenesis [4]. 
Topiramate, a new anti epileptic drug also implicate the calcium 
uroliths by its renal tubular acidosis induced by its carbonic 
anhydrase enzyme [41]. HIV-positive patients are more prone to 
develop these drugs induced stones when they are treated with 
lithogenic drugs like indinavir and sulfamides (sulfamethoxazole 
and sulfadiazine) [42]. 
2, 8-Dihydroxyadenine stones 
Rare form of stones that results from a very rare form of adenine 
phosphoribosyl-transferase (APRT) deficiency inherited renal stone 
disease, progressively ends with renal failure. In APRT deficiency 
condition, it accumulates large amounts of adenine which then 
metabolized to nephrotoxic 2, 8-dihydroxyadenine by xanthine 
oxidase enzyme. Since it is a life threatening, the early diagnosis and 
treatment with allopurinol is needed [4]. 
Risk factors  
The potential risk factors in a susceptible individual for inducing the 
stone formation are characterized as follows:  
 
Fig. 1: Risk factors in inducing the stone formation. 
 
• Metabolic disorders like hypercalciuria, hyperuricosuria, 
hypercalcaemia, hypocitraturia, hypomagnesuria. 
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• Drug induced. 
• Hyperparathyroidism. 
• Dehydration. 
• Hot climates. 
• Anatomical abnormalities. 
• Increased urinary pH. 
• Lower urinary volume. 
• Infections. 
• Hypertension. 
• Metabolic acidosis. 
Genetics of urolithiasis 
In a multifactorial etiopathogenesis, genetic factors are known to 
play a significant role. Several studies were intended to discover the 
genetic linkage associated with this disease had succeeded in 
identifying the genes and their genetic polymorphism. The vitamin D 
receptor (VDR) gene confined to a region of chromosome 12 is 
greatly concerned with the functional aspects of calcium 
metabolism. But when the genetic polymorphism of FokI and TaqI 
VDR gene can results in hypercalciuria induced familial idiopathic 
CaOx urolithiasis [43, 44, 45]. Interleukin-1, pro-inflammatory and 
immunopathological cytokine also had an important role in inducing 
the bone resorption. Thus, induced bone resorption can results in 
idiopathic hypercalciuria which predisposes to calcium uroliths. 
Thus a genetic polymorphism of interleukin-1β (IL-1β) and 
interleukin-1 receptor antagonist (IL-1Ra) genes located on 
chromosome 2 are greatly concerned in idiopathic hypercalciuria 
implicated calcium uroliths [46, 47]. Calcitonin (CT), a polypeptide 
hormone of the thyroid gland is functionally associated with the 
inhibition of bone reabsorption thereby promoting the urinary 
calcium excretion. Therefore calcitonin receptor (CTR) gene located 
on chromosome 7 which is associated with calcium metabolism is 
found to be immensely associated with CaOx urolithiasis by its 
genetic polymorphism [48, 49].  
Urokinase, a proteolytic enzyme involving in the fibrinolytic 
pathway also involved in the prevention of stone growth by its 
proteinase activity on the matrix protein which can influence the 
stone formation. However, a change in the protein structure can acts 
as a matrix protein in inducing the CaOx urolithiasis by its genetic 
polymorphism over the urokinase gene of 3´ untranslated region 
(3´-UTR) located in chromosome 10 [50, 51, 52, 53]. As the cellular 
injury along with the damage of cellular integrity is evident in stone 
formation, E-cadherin (CDH-1) which is an epithelial junction 
protein responsible for conserving the cellular integrity, epithelial 
cell development and organization is need to be considered in 
evaluating the etiological factor of stone formation. There exists a 
strong relationship with the CDH-1 gene (located on chromosome 
16) 3´ untranslated region (3´-UTR) polymorphism in CaOx 
urolithiasis [54, 55]. Vascular endothelial growth factor (VEGF), a 
glycoprotein responsible for neovascularisation also associated with 
the CaOx urolithiasis by its VEGF gene polymorphism [56]. As the 
urinary stones are generally complied with the cell death, cyclin 
dependant kinase inhibitor that monitors the cell cycle is need to be 
considered in describing the genetic susceptibility of urolithiasis 
[57]. One such inhibitor is p21 protein, a downstream protein of p51 
that inhibits G1/S phase of life cycle. The arginine form of p21 gene 
had less marginal susceptibility to CaOx urolithiasis [58]. The other 
genetic mutations of chloride channel (CLCN5) gene located on X 
chromosome generally linked with disorders of Dent’s disease, X-
linked recessive nephrolithiasis type I X-linked recessive 
hypophosphatemic rickets which are characterized by increased 
excretion of calcium that predisposes the patient to calcium uroliths 
formation [59].  
Cystinuria induced urolithiasis is evident from the genetic mutations 
of genes responsible for the transportation of cystine from 
interstitial epithelium and proximal renal tubule. Genetic mutations 
of SLC3A1 and SLC7A9 genes are the known causes for type A and 
type B cystinuria which can predispose the cystinuria patients to 
cystine uroliths [60]. 
 
Table 1: Genetics of urolithiasis 
Gene Defect Urolithiatic condition 
FokI and TaqI VDR gene Genetic polymorphism Familial idiopathic CaOx urolithiasis 
IL-1β receptor gene Genetic polymorphism Idiopathic hypercalciuria induced calcium uroliths 
IL-1Ra gene Genetic polymorphism Idiopathic hypercalciuria induced calcium uroliths 
CTR gene Genetic polymorphism Calcium Oxalate urolithiasis 
Urokinase gene Genetic polymorphism Calcium Oxalate urolithiasis 
CDH-1 gene Genetic polymorphism Calcium Oxalate urolithiasis 
p21 gene Arginine form of p21 Calcium Oxalate urolithiasis 
CLCN5 gene X-linked recessive allele Hypophosphatemic rickets induced calcium uroliths 
SLC3A1 gene  Genetic mutation Type A cystinuria induced cystine uroliths 
SLC7A9 gene Genetic mutation Type B cystinuria induced cystine uroliths 
HPRT gene Genetic mutation Uric acid uroliths 
PRPP gene Genetic mutation Uric acid uroliths 
G6Pase gene Genetic mutation Uric acid uroliths 
APRT gene Autosomal recessive allele 2, 8 dihydroxyadenine induced urolithiasis 
Genetic mutations of hypoxanthine guanine phosphoribosyltransferase (HPRT) gene (Lesch-Nyhan syndrome), Phosphoribosyl-pyrophosphate 
synthetase (PRPP) gene (Phosphoribosyl-pyrophosphate synthetase super activity) and Glucose 6 phosphatase (G6Pase) gene (Glycogen storage 
disease type 1) can predispose the patient to uric acid uroliths [59]. In autosomal recessive fashion, the genetic defect of APRT gene located on 
chromosome 16 can ultimately lead to 2, 8 dihydroxyadenine induced urolithiasis [61]. While several other studies also found out the genetic 
polymorphism of androgen and estrogen receptor genes involvement in the urolithiasis especially in men [62].  
 
Pathophysiology 
The exact cascade of pathophysiological events in the pathogenesis 
of urolithiasis is still remained to be unclear. In general, the 
pathophysiology of urolithiasis largely depends on the phenotype of 
stone formed in the urinary tract. In CaOx urolithiasis, the nucleation 
of CaOx resulted from decreased solubility with the increase in uric 
acid levels [63, 64]. In addition to this, Randall plaques that are 
resulted from precipitation and accumulation of CaOx in the 
basement membrane and sub epithelial space of renal papillae that 
eventually lead to the calculi induction [65]. The other mechanism to 
adopt the pathogenesis of CaOx stone formation, when there is an 
imbalance in the promoters and inhibitors of crystallization 
compounds. However, the drug induced CaOx urolithiasis cannot be 
ruled out by the drugs like loop diuretics, acetazolamide, antacids, 
glucocorticoids and theophylline.  
Vamsi et al. 
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In particularly considering the crystal nucleation and aggregation 
aspects of CaOx urolithiasis, several theories like epitaxy, matrix and 
inhibitor theories have been proposed in order to hypothesize the 
exact events of crystal nucleation and aggregation of CaOx. Epitaxy 
theory proposed the heterogeneous nucleation of CaOxcan be 
induced by the supersaturation of sodium urate and uric acid 
crystals in urine epitaxially. Matrix theory assumes the role of some 
urinary macromolecules in the CaOx crystal nucleation and growth 
by acting as a matrix for stone induction. In inhibitor theory, the role 
of inhibitor substances like citrate, pyrophosphate, magnesium in 
inhibiting the nucleation and growth of CaOx has been described [66]. 
Stress induced secretion of vasopressin and Adrenocorticotropic 
hormone (ACTH) results in hypertonic urine and elevated serum 
calcium levels which explain the mechanism of stress as a 
pathophysiological factor in inducing the CaOx urolithiasis [67]. 
In struvite stone pathogenesis, the increased pH due to microbial 
conversion of urea to carbon dioxide and ammonia tends to be the 
key pathological event for the crystallization of struvite stones. The 
other non urease microbes like E. coli debated that the increased 
matrix production favors the adherence of struvite crystals at the 
site of calculi induction [12]. In uric acid stones, the pathological 
mechanisms seem to be very diverse in nature. It may be idiopathic, 
acquired and congenital mechanisms in inducing the pathogenesis. 
Clinically it was evident that the hyper uricosuria in uric acid stones 
pathogenesis that resulted from the high intake purine rich diet and 
drugs (losarton, probenecid) that impair the absorption of 
reabsorption of uric acid. More over to this, hyper uricosuria 
lowered the pH (<5.5) which favors the induction of uric acid 
nephrolithiasis. However, idiopathically there was uric acid 
nephrolithiasis even with normal urinary uric acid and pH levels, 
considered as idiopathic uric acid nephrolithiasis (IUAN) [68, 69]. In 
cystine stones, predominantly the autosomal recessive genetical 
abnormality of proximal tubule impairs the reabsorption of cystine 
by APRT deficiency. Thus developed cystinuria becomes a 
predisposing factor for cystine nephrolithiasis. 
Despite of the phenotypic nature of uroliths, several other theories 
have been employed for the detailing the physiochemical process of 
stone formation irrespective of its phenotype nature. These are 
categorized as intracellular/interstitial theory and 
extracellular/intratubular theory. The intracellular theory primarily 
depicts the key pathological implicating event of renal lesion which 
potentiates the nucleation step of nephrolithiasis. The extracellular 
theory stated the importance of other intratubular factors in 
implicating the pathogenesis is presence of matrix components, 
alterations in urinary pH, alterations in urinary composition, 
lithogenic diet along with trigger factors like dehydration and rate of 
growth in crystallization [70].  
In addition to the above stated multifactorial pathogenesis, the role 
of several proteins in the pathogenesis cannot be ruled out. 
Nephrocalcin from renal tubular origin inhibits the CaOx 
crystallization by impairing the aggregation of CaOx crystals. 
Inhibitory effect on the lithogenesis was reported with Tamm-
Horsfall protein (THP) of the thick ascending limb of loop of Henle 
and early distal convoluted tubular origin. It was reported that the 
crystal matrix protein of the thick ascending limb of loop of Henle 
and early distal convoluted tubular origin can retard the CaOx 
crystallization [71]. Several studies also demonstrated that the 
damaged cellular membrane, damaged proximal tubules or loop of 
Henle, injured urothelium after treatment with nephrotoxic agents 
such as gentamicin, induce nucleation of CaOx crystals at a lower 
supersaturation [72].  
In conclusion with the above stated possible pathophysiological 
mechanisms, the pathophysiology of urolithiasis is evident from 
multifactorial complex cascade of pathogenic events. 
Clinical presentation 
The majority of clinical symptoms seem to be asymptomatic and 
they are noticed in investigations of other conditions. 
• Sudden renal colic or ureteric colic. 
• Radiating pain towards the groin and testicular region. 




• Urinary retention. 
• Rigors and fever. 
• Nausea and vomiting. 
• Pyonephrosis [73]. 
Diagnosis 
General diagnosis 
• Physical examination of any tenderness at the affected site. 
• Electrolyte and urea level analysis in urine 
• Dipstick analysis for the detection of Haematuria. 
• pH of the urine. 
- When pH > 7.5 in urine indicates the infection (infection stones). 
- When pH <5.5 in urine indicates the presence of uric acid stones 
[73]. 
• Haematuria. 
• Renal and biliary colic. 
• Investigating the X-ray of urinary tract for the presence of stones. 




- Renal infarction. 
- Retroperitoneal fibrosis. 
- Testicular torsion. 
- Tumor. 
- Necrosis of renal papillae. 
• Non-urologically  
- Biliary colic. 
- Abdominal aortic aneurysm. 
- Appendicitis. 
- Ovarian cyst torsion. 
- Fallopian tube Infection and inflammation, clinically called as 
salpingitis. 
- Pouches in colonic region which leads to a painful condition of 
diverticulitis. 
Clinical management 
Management of acute stones 
Acute therapy of nephrolithiasis mainly intended to manage pain, 
forcing the diuresis and hydration. In acute conditions non steroidal 
and narcotic analgesics seems to be prominent therapeutic choice in 
the management of pain. In conditions where the opoids are 
contraindicated, a combination of dextropropoxyphene and 
paracetamol is used in acute setting [71]. But the cyclo oxygenase 
inhibitors should be avoided in renal insufficiency conditions [74]. 
Elimination of the stones can be managed by inducing diuresis very 
Vamsi et al. 
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effectively by the increased fluid intake of at least >2L daily. But 
forced diuresis induced worsening pain, ureteral pain and 
hydronephrosis need to be monitored very carefully.  
Management of Chronic stones 
A. Specific measures 
In calcium stones-hypercalciuria, thiazide diuretics administration 
can enhance the tubular reabsorption of calcium and ablate the 
intestinal calcium absorption [71]. In recurrent idiopathic conditions 
of calcium stones-hypercalciuria, indapamide stood to be as a best 
choice for its management [75]. Alternative to this, the usage of 
potassium sparing diuretics can spare the potassium in order to 
replace the phosphorous loss. Potassium citrate supplementation 
also acts as an additive therapy in order to inhibit the crystal 
aggregation by the citrate excretion. In calcium stones-
hyperoxaluria, the effective management includes fluid intake, 
alkalinisation of urine and restriction over the intake of foods rich 
with high oxalate content. Clinically the therapeutic choice is the 
combinational therapy using calcium carbonate along with 
potassium citrate/ along with magnesium gluconate [76]. In calcium 
stones-hypocitraturia, the pathological intervention can be made by 
the supplementation with potassium citrate. This supplementation 
effectively replaces the loss citrate levels in order to form a complex 
with calcium to eliminate it [71]. In the management of calcium 
stones-hyperuricosuria, the treatment should include the restriction 
over the dietary purine intake and increased water uptake along 
with allopurinol supplementation [77]. 
 
Table 2: Herbal treatment of urolithiasis 
Plant Part used Screening model Reference 
Achyranthes aspera (Amaranthaceae) Roots 
Roots 










Alcea rosea (Malvaceae) Root  In vivo [93] 
Ammi visnaga (Apiaceae) seeds In vivo [94] 
Berberis vulgaris (Beriberidaceae) Root  In vivo [95] 
Berginia ligulata (Saxifragaceae) Rhizomes  In vitro and in vivo [96] 
Boerhavia diffusa (Nyctaginaceae) Whole plant In vitro [97] 
Bombax cieba (Malvaceae) Fruit  In vivo [98] 
Bryophyllum pinnatum (Crassulaceae) Whole plant In vitro [97] 
Camellia sinensis (Threaceae) Leaves  In vivo [99] 














Costus spiralis (Costaceae) Whole plant In vivo [106] 
Crataeva nurvala (Capparaceae) Bark In vivo [107] 
Cynodon dactylon (Poaceae) Roots  In vivo [108] 









Hibiscus sabdariffa (Malvaceae) Calyces  In vivo [112] 
Lagenaria siceraria (Cucurbitaceae) Fruit  In vivo [113] 
Leea macrophylla (Vitaceae) Whole plant In vivo [114] 
Moringa oleifera (Moringaceae) Roots  In vivo [7] 
Musa paradisiaca (Musaceae) Stem  In vivo [115] 
Nigella sativa (Rananculaceae) Seeds  In vivo [116] 
Origanum vulgare (Lamiaceae) Aerial parts In vitro and in vivo [117] 
Orthosiphon grandiflorum (Lamiaceae) Leaves  In vivo [118] 
Paronychia argentea (Caryophyllaceae) Aerial parts In vivo [2] 
Petroselinum sativum (Apiaceae) Aerial parts and roots In vivo [119] 









Pinus eldarica (Pinaceae) Fruit  In vivo [123] 
Plectranthus amboinicus (Lamiaceae) Leaves In vivo [124] 






Quercus salicina (Fagaceae) Leaves and branches 
Leaves and twigs 




Raphanus sativus (Brassicaceae) Tubercles  In vivo [129] 
Rotula aquatica (Boraginaceae) Roots  In vitro [104] 
Rubia cordifolia (Rubiaceae) Roots  In vivo [1] 
Salvadora persica (Salvadoraceae) Leaves  In vivo [130] 
Sesbania grandiflora (Fabaceae) Twigs  In vivo [131] 
Solanum xanthocarpum (Solanaceae) Fruits  In vivo [132] 
Terminalia arjuna (Combretaceae) Bark  In vitro [133] 
Terminalia chebula (Combretaceae) Fruit  In vitro (Cell lines) [134] 









Trigonella foenum-graceum (Fabaceae) Seeds  In vivo [138] 
Vaccinium oxycoccus (Ericaceae) Juice  Clinical trials [139] 
Vamsi et al. 
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The principles of treatment for uric acid stones include effective 
alkalinisation of urine to 6.5 (pH), dietary restriction of purine rich 
foods and adequate water intake. Treatment options include 
potassium citrate and acetazolamide for effective alkalinisation; and 
administration of allopurinol and febuxostat to minimize the uric 
acid synthesis [78]. As the struvite stones are the infectious stones 
manifested by the bacterial infections, the antibiotic therapy should 
be recommended for a period of at least three months [30]. In 
specifically, the urease inhibition is preferred in certain cases of 
patients with acetohydroxamic acid or flurofamide [79, 80]. Where 
as in the cystine stones management, the approach is aimed at 
alkalinisation of urine by potassium citrate to pH >7.4, adequate 
water intake aimed to be more than 4L /day and administration of 
d-pencillamine [81]. The other treatment options include the therapy 
of tiopronin (α–mercaptopropionyl glycine), ascorbic acid and 
angiotensin converting enzyme (ACE) inhibitors [82, 83]. While the 
treatment option of captopril, an ACE inhibitor is still remains to be 
unclear. But it is used when the tiopronin therapy is unsuccessful [84]. 
B. Surgical procedures 
Surgical procedures are adopted when the conventional system of 
therapy fails to eliminate the uroliths. Moreover it became an effective 
management application when the stones are larger than 5 mm in size 
and failed to pass by the conventional system of medicine [85]. Surgical 
procedures like Extracorporeal shock wave lithotripsy (ESWL), 
Percutaneous nephrolithotomy (PCNL), Ureteroscopy and open surgery 
are employed in the surgical management of nephrolithiasis. While 
laparoscopy equipment and instrumentation is under clinical 
consideration to evolve as a treatment option.  
• In ESWL shock waves are used to break the stones which then 
they pass spontaneously.  
• In PCNL, nephroscope is employed for the removal of stones 
especially for larger stones (>2 cm), cystine and Staghorn calculi. 
• A laser beam is used in ureteroscope for the disintegration of 
stones. It is ideally best opted for the fragmentation of distal ureteral 
stones. 
• Open surgery held to an effective choice when there is treatment 
failure of above surgical interventions, co-morbid with the other 
diseased condition and multiple stones. 
The success rate of these surgical procedures greatly depends on the 
location, stone burden, composition and hardness of the calculi. But 
these surgical interventions are very expensive with high recurrence 
rate [86]. Despite of their highly targeted intervention, they were 
limited by renal damage, renal tissue necrosis and damage to the 
surrounding organs [87]. 
Prevention 
The following measures are opted to be best suitable preventive 
measures in the management of urolithiasis. 
• Increase uptake of water up to 2L daily.  
• Maximizing the urinary output. 
• Limiting the use of drugs that induce uroliths. 
• Minimizing the intake of animal protein. 
• Low intake of sodium. 
• Lowering the dietary intake of purine and oxalate rich food. 
• Limitation of dietary intake of calcium. 
• Monitoring the body weight gain [71]. 
Herbal therapy 
In the medical management of urolithiasis, phytotherapy opted to be 
an alternative or adjunctive therapy. Based on in vitro, in vivo and 
clinical studies, it was revealed that these phytotherapeutic agents 
acts by diuretic, antioxidant, increasing urinary citrate, 
antimicrobial, and other possible mechanisms [88]. The following 
plants are claimed to possess the antiurolithiatic activity. 
CONCLUSION 
The clinical management of urolithiasis is still remained to be 
unclear with the modest understanding of genetics and 
pathogenesis. Detailing the genetical, pathophysiological and 
management aspects will provide a treasure trove for the clinicians 
to manage urolithiasis very effectively. As the conventional therapy 
fails to meet the demands of management of urolithiasis, herbal 
therapy opted to be an alternative or adjunctive choice in its 
management. Hence this review also summarizes the potent herbal 
litholytic agents. But further extensive studies are needed in order to 
understand the exact cascade of pathogenesis, genetics and clinical 
therapy of urolithiasis. 
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